POST Online Media Lite Edition



 

Roche attempt to retool arthritis drug for coronavirus pneumonia fails trial

Christian Fernsby |
Roche announced that the phase III Covacta study of Actemra RoActemra tocilizumab did not meet its primary endpoint of improved clinical status in hospitalised adult patients with severe coronavirus associated pneumonia.

Article continues below



Topics: ROCHE   

In addition, the key secondary endpoints, which included the difference in patient mortality at week four, were not met; however, there was a positive trend in time to hospital discharge in patients treated with Actemra RoActemra.

The Covacta study did not identify any new safety signals for Actemra RoActemra.

Further analysis of the trial results is needed to fully understand the data.

The results will be submitted for publication in a peer-reviewed journal.


What to read next

Netherlands has confidence in Roche commitments to help solve problems with test materials
Roche to invest 450 million Swiss Francs in China
AVEO Pharmaceuticals pays $4m to settle SEC fraud charges